Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims:
advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags:
FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns:
homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations:
specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…
Esperoct (Novo Nordisk)
(https://esperoct.com) 📸 Data Snapshot: May 30, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Hemophilia A Treatment | Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] (https://esperoct.com)
Title
Hemophilia A Treatment | Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]
Meta
Esperoct® is indicated as an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Read important safety & prescribing info on this page.
H1 Flexibility in hemophilia A
H2 Michael Norwood
H2 Thank you!
H2 Every experience matters
H2 Yes, women can have hemophilia too.
H2 Set a reminder for your calendar
H2 Who should not use Esperoct®?
H2 What is the most important information I need to know about Esperoct®?
H2 What should I tell my healthcare provider before using Esperoct®?
H2 What are the possible side effects of Esperoct®?
H2 Who should not use Esperoct®?
H2 Who should not use Esperoct®?
H2 What is the most important information I need to know about Esperoct®?
H2 What should I tell my healthcare provider before using Esperoct®?
H2 What are the possible side effects of Esperoct®?
H2 Who should not use Esperoct®?
H2 What is the most important information I need to know about Esperoct®?
H2 What should I tell my healthcare provider before using Esperoct®?
H2 What are the possible side effects of Esperoct®?
NAV_HEADING_REPEATED_BODY_FOOTER Storage and Portability | Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] (https://esperoct.com/flex-factor.html)
Title
Storage and Portability | Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]
Meta
Learn about the storage temperature and flexible portability of Esperoct®. Use the heat map to explore regions of the United States and learn about their temperatures. Read important safety & prescribing info on this page.
H1 Stay prepared with a flexible EHL treatment, even if things heat upa
H2 The highest storage temperature of all extended half-life (EHL) products
H2 Feel prepared for a day of adventure or be ready for wherever life takes you
H2 Temperatures can fluctuate when you’re on the go.
H2 Stay protected on the go
H2 Who should not use Esperoct®?
H2 What is the most important information I need to know about Esperoct®?
H2 What should I tell my healthcare provider before using Esperoct®?
H2 What are the possible side effects of Esperoct®?
H2 Who should not use Esperoct®?
H2 Who should not use Esperoct®?
H2 What is the most important information I need to know about Esperoct®?
H2 What should I tell my healthcare provider before using Esperoct®?
H2 What are the possible side effects of Esperoct®?
H2 Who should not use Esperoct®?
H2 What is the most important information I need to know about Esperoct®?
H2 What should I tell my healthcare provider before using Esperoct®?
H2 What are the possible side effects of Esperoct®?
NAV_HEADING_REPEATED_BODY_FOOTER Community Voices | Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] (https://esperoct.com/community-voices.html)
Title
Community Voices | Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]
Meta
Hear from patients about their experience with Esperoct®. Read important safety & prescribing info on this page.
H1 “Hemophilia–has it impacted me? Yes. But does it stop me? No.”
H2 Every experience matters
H2 Community matters
H2 Michael Norwood
H2 Thank you!
H2 Who should not use Esperoct®?
H2 What is the most important information I need to know about Esperoct®?
H2 What should I tell my healthcare provider before using Esperoct®?
H2 What are the possible side effects of Esperoct®?
H2 Who should not use Esperoct®?
H2 Who should not use Esperoct®?
H2 What is the most important information I need to know about Esperoct®?
H2 What should I tell my healthcare provider before using Esperoct®?
H2 What are the possible side effects of Esperoct®?
H2 Who should not use Esperoct®?
H2 What is the most important information I need to know about Esperoct®?
H2 What should I tell my healthcare provider before using Esperoct®?
H2 What are the possible side effects of Esperoct®?
NAV_REPEATED_BODY_FOOTER Women With Hemophilia A | Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] (https://esperoct.com/women-in-hemophilia.html)
Title
Women With Hemophilia A | Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]
Meta
Esperoct® is an injectable treatment for all individuals with hemophilia A, including women and girls, to prevent or reduce bleeding episodes. Read important safety & prescribing info on this page.
H1 Are you a woman or girl who lives with hemophilia A or suspects you may have it?
H2 Do you feel like your doctor is not listening to you?
H2 Track Your Symptoms & Share With Your Doctor
H2 You deserve a diagnosis and treatment options for your hemophilia
H2 It’s Time to Prioritize Your Health
H2 Michael Norwood
H2 Thank you!
H2 Who should not use Esperoct®?
H2 What is the most important information I need to know about Esperoct®?
H2 What should I tell my healthcare provider before using Esperoct®?
H2 What are the possible side effects of Esperoct®?
H2 Who should not use Novoeight®?
H2 What is the most important information I need to know about Novoeight®?
H2 What should I tell my healthcare provider before using Novoeight®?
H2 What are the possible side effects of Novoeight®?
H2 Who should not use Esperoct®?
H2 Who should not use Esperoct®?
H2 What is the most important information I need to know about Esperoct®?
H2 What should I tell my healthcare provider before using Esperoct®?
H2 What are the possible side effects of Esperoct®?
H2 Who should not use Novoeight®?
H2 What is the most important information I need to know about Novoeight®?
H2 What should I tell my healthcare provider before using Novoeight®?
H2 What are the possible side effects of Novoeight®?
H2 Who should not use Novoeight®?
H2 What is the most important information I need to know about Novoeight®?
H2 What should I tell my healthcare provider before using Novoeight®?
H2 What are the possible side effects of Novoeight®?
H2 Who should not use Esperoct®?
H2 What is the most important information I need to know about Esperoct®?
H2 What should I tell my healthcare provider before using Esperoct®?
H2 What are the possible side effects of Esperoct®?
H2 Who should not use Novoeight®?
H2 What is the most important information I need to know about Novoeight®?
H2 What should I tell my healthcare provider before using Novoeight®?
H2 What are the possible side effects of Novoeight®?
H3 According to a Novo Nordisk survey of doctorsb:
H3 Esperoct® is an extended half-life (EHL) treatment that can be used as prophylaxis or on demand.
H3 Novoeight® is a standard half-life (SHL) treatment that can be used as prophylaxis or on demand.
H3 Contact a Novo Nordisk Rare Blood Community Liaison (RBCL)
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://esperoct.com) Hemophilia A Treatment | Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]
Discover your treatment personality type! Take the quiz [IMG: Envelope icon] Get updates [IMG: Envelope icon] Get updates [IMG: Storage temperature range icon] Vaughn has hemophilia A and uses Esperoct® [H1] Flexibility in hemophilia A Esperoct® offers the highest storage temperature (up to 104 °F) of all EHLs along with bleed protection for all ages.a Explore Flex Factor EHL=extended half-life. aPrior to reconstitution, Esperoct® can be stored from 36 °F to 46 °F for up to 30 months, at room temperature up to 86 °F for up to 12 months, or up to 104 °F for up to 3 months. See Prescribing Information for complete product storage information. is not a valid ZIP code A valid ZIP code will have 5 numbers. Please try again. Your zip code is Change ZIP. Apply new ZIP code. Update ZIP Technical error We are experiencing an unexpected technical error. Please try again later. Please enter your zip code Update Zip [H2] Michael Norwood “I love helping people. The patient connection is my favorite part. Finding opportunities to impact communities while challenging myself to learn something new every day.” Get started Hello! I look forward to connecting with you. Please provide the following information and I’ll be in touch: [H2] Thank you! You have successfully signed up for Esperoct® updates. We’ll be in touch! I'm finished [IMG: Person doing yoga icon] Tammy has hemophilia A and uses Esperoct® [H1] "This treatment seamlessly fits into my schedule" Esperoct® offers on-the-go bleed protection for people of all ages with hemophilia A.a Learn more about how Esperoct® can fit into your lifestyle. Explore Flex Factor aPrior to reconstitution, Esperoct® can be stored from 36 °F to 46 °F for up to 30 months, at room temperature up to 86 °F for up to 12 months, or up to 104 °F for up to 3 months. See Prescribing Information for complete product storage information. [H2] Every experience matters We’re shining a spotlight on a few community voices and their stories about living and managing life with hemophilia A. See patient stories Tammy has hemophilia A and uses Esperoct® [H2] Yes, women can have hemophilia too. You deserve a diagnosis and treatment options for your hemophilia. It’s time to challenge the misconception that women and girls can only be “carriers" of hemophilia. Many women feel that their doctors dismiss or minimize their actual symptoms, but we’ve developed tools to help you make sure that you’re heard. Ready to start the conversation? [IMG: Esperoct® box and phone with calendar showing] [H2] Set a reminder for your calendar Stay on track with your Esperoct® infusion schedule and set up an infusion reminder that goes directly to your calendar. Get started [IMG: Esperoct® box and phone with calendar showing]
3625 chars
SUB-PAGE (https://esperoct.com/flex-factor.html) Storage and Portability | Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]
Discover your treatment personality type! Take the quiz Get updates Get updates [H1] Stay prepared with a flexible EHL treatment, even if things heat upa Esperoct® offers the broadest temperature stability, for all ages.a Along with compact packaging for portability when you’re on the go. aPrior to reconstitution, Esperoct® can be stored from 36 °F to 46 °F for up to 30 months, at room temperature up to 86 °F for up to 12 months, or up to 104 °F for up to 3 months. See Prescribing Information for complete product storage information. [IMG: Open suitcase with landscapes] [IMG: Storage temperature icon] [H2] The highest storage temperature of all extended half-life (EHL) products Esperoct® is the only EHL product that can be stored from 86 ºF to 104 ºF (for up to 3 months). Why does storage temperature matter? If a treatment becomes too hot or too cold, it could affect how it works. The high temperature stability of Esperoct® (from 36 °F to 104 °F) can help you stay prepared for life’s adventures or unexpected moments.a [H2] Feel prepared for a day of adventure or be ready for wherever life takes you Heading to the beach? Going on vacation? In a power outage? Enjoy a day at the beach come rain or shine Take that vacation and bring Esperoct® with you Feel protected in a power outage [H2] Temperatures can fluctuate when you’re on the go. Explore the regions on this map to learn more about temperatures across the country. [H2] Stay protected on the go Carry Esperoct® and your supplies with you in a portable, reusable kit that has been designed to fit into your life. Compact packaging–for easy storage [IMG: Esperoct® box, vials, and travel kit] Esperoct® is available in six dosage strengths: 500 IU, 1000 IU, 1500 IU, 2000 IU, 3000 IU, 4000 IU. Vaughn has hemophilia A and uses Esperoct® “I really like that Esperoct® is stable at room temperature and up to 104 ºF. I can just throw it in my backpack and go.” Tammy has hemophilia A and uses Esperoct® Hear more from Tammy and other voices in the hemophilia A community. Hear their stories [IMG: Shield with blood droplet icon] Stay protected from bleeds With Esperoct® you can dose less often without sacrificing protection.b Find out more [IMG: Box and injection pen icon] Ready to get started? We’ll guide you through the steps to take before your first infusion. Get started bCompared to SHL products, 50% fewer infusions when administered every other day and 40% fewer when administered 3x weekly.
3394 chars
SUB-PAGE (https://esperoct.com/community-voices.html) Community Voices | Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]
Discover your treatment personality type! Take the quiz [IMG: Envelope icon] Get updates [IMG: Envelope icon] Get updates [H1] “Hemophilia–has it impacted me? Yes. But does it stop me? No.” Vaughn lives with hemophilia A and uses Esperoct® [H2] Every experience matters Hear inspirational stories from people like you, who use Esperoct®. [IMG: Tammy posing] [IMG: Bradley standing with his arms crossed] [H2] Community matters “This community is so amazing. Everybody connects right away.” Craig lives with hemophilia A, works for Novo Nordisk, and uses Esperoct® is not a valid ZIP code A valid ZIP code will have 5 numbers. Please try again. Your zip code is Change ZIP. Apply new ZIP code. Update ZIP Technical error We are experiencing an unexpected technical error. Please try again later. Please enter your zip code Update Zip [H2] Michael Norwood “I love helping people. The patient connection is my favorite part. Finding opportunities to impact communities while challenging myself to learn something new every day.” Get started Hello! I look forward to connecting with you. Please provide the following information and I’ll be in touch: [H2] Thank you! You have successfully signed up for Esperoct® updates. We’ll be in touch! I'm finished [IMG: Magnifying glass with a paper icon] Looking for more resources? We’ve gathered resources that you may find helpful. View the resources
2224 chars
SUB-PAGE (https://esperoct.com/women-in-hemophilia.html) Women With Hemophilia A | Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]
Discover your treatment personality type! Take the quiz [H1] Are you a woman or girl who lives with hemophilia A or suspects you may have it? You’re not alone. You deserve a diagnosis and treatment options for your hemophilia—but women with hemophilia A may not always be diagnosed. That’s why we’ve developed a Self-Advocacy Guide to help you share symptoms with your doctor and get the right treatment for you. Download the Self-Advocacy Guide [IMG: Be embowered: you can advocate for an appropriate diagnosis and treatment] [H2] Do you feel like your doctor is not listening to you? [IMG: 48% of the women and girls who had hemophilia or were carriers who visited a Hemophilia Treatment Center (HTC) were diagnosed with hemophilia. In a real-world study of data collected from people receiving care in HTCs from 2012-2020.] [IMG: 48 percent icon] of the women and girls who had hemophilia or were carriers who visited a Hemophilia Treatment Center (HTC) were diagnosed with hemophilia.a aIn a real-world study of data collected from people receiving care in HTCs from 2012-2020. [IMG: Woman and girl icon] According to the NBDF, as many as 50% of girls and women who are carriers for hemophilia A or B have factor 8 or 9 levels below 50% and are at risk for bleeding symptoms or heavy bleeding related to menstruation or pregnancy. All people with inherited bleeding disorders should have access to care within a Hemophilia Treatment Center or other clinical program with expertise in bleeding disorders. If you are experiencing bleeding symptoms, it’s time for you and your doctor to talk about it. Download Your Guide HTC=hemophilia treatment center; MASAC=Medical and Scientific Advisory Council; NBDF=National Bleeding Disorders Foundation; WFH=World Federation of Hemophilia. [H3] According to a Novo Nordisk survey of doctorsb: [IMG: 32% (n=12)] of providers do not always follow clinical guidelines (MASAC guidelines) for women and girls & [IMG: 81% (n=35)] said women with inherited bleeding disorders (including "carriers") experience more difficulty obtaining a diagnosis for their bleeding disorder vs. affected men bIn a 2021 survey of 49 HCPs that aimed to assess the barriers to increasing access to care for women with bleeding disorder diagnoses or symptoms of a bleeding disorder. HTC=hemophilia treatment center; MASAC=Medical and Scientific Advisory Council; NBDF=National Bleeding Disorders Foundation; WFH=World Federation of Hemophilia. [H2] Track Your Symptoms & Share With Your Doctor Your symptoms matter. In one study, nearly 2 out of 3 hemophilia “carriers” had heavy menstrual bleeding—periods lasting longer than 7 days, changing pads after less than 2 hours, and/or passing blood clots larger than 1 inch or the size of a quarter. This can be linked to: [IMG: Symptoms: Missed work & school, interruptions to social life, fatigue, mental health challenges, financial cost, poor sleep] Signs and symptoms of hemophilia in women and girls should not be dismissed. Remember, you know your body best. You can use the Self-Advocacy Guide to record any pain, swelling, and bruising you feel, which could be signs of a bleed. Bring these records with you to your doctor to help guide your conversation. Start tracking: Know your symptoms to better advocate for yourself Get your Self-Advocacy Guide [IMG: Recurring bleeds in joints can also cause long-term damage, including: chronic pain, chronic joint disease] Recurring bleeds in joints can also cause long-term damage, including: [IMG: Chronic pain, chronic join disease icons] Signs and symptoms of hemophilia in women and girls should not be dismissed. Remember, you know your body best. You can use the Self-Advocacy Guide to record any pain, swelling, and bruising you feel, which could be signs of a bleed. Bring these records with you to your doctor to help guide your conversation. Start tracking: Know your symptoms to better advocate for yourself Get your Self-Advocacy Guide Tammy’s Been There Too Like many women, Tammy struggled to get the right treatment for her hemophilia—but now she's focusing on living her life on her terms. Meet Tammy: Sharing our stories makes a difference [H2] You deserve a diagnosis and treatment options for your hemophilia Flexxibility Factors on your termsc Explore 2 options for women, girls, and people assigned female at birth with hemophilia A. [IMG: Pink purse] [IMG: Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] logo] [H3] Esperoct® is an extended half-life (EHL) treatment that can be used as prophylaxis or on demand. Learn more [IMG: Beach bag] [H3] Novoeight® is a standard half-life (SHL) treatment that can be used as prophylaxis or on demand. Learn more cPrior to reconstitution, Esperoct® and Novoeight® can be stored from 36 °F to 46 °F for up to 30 months, at room temperature up to 86 °F for up to 12 months, or up to 104 °F for up to 3 months. See Prescribing Information for complete product storage information. [IMG: Woman climbing mountain] You’re In Charge If you are experiencing bleeding symptoms, don't let your healthcare provider gloss over it. Provide your doctor with documentation of your symptoms. Make sure you follow up and ask questions—if something doesn’t make sense, say so. Prepare for your appointment so you can feel confident speaking up for yourself. Check out more tips in your Self-Advocacy Guide! [H2] It’s Time to Prioritize Your Health According to WFH guidance, women, girls, and people assigned female at birth with hemophilia A should be treated the same as men and boys—but when it comes to treatment, they may not have been. That’s why we’ve developed the Self Advocacy Guide to help you talk to your doctor about your hemophilia symptoms, receive the correct diagnosis, and get the right treatment for you. Learn more: These FLEXXIBLE treatment options could fit your lifestyle Explore Esperoct® Get to know Novoeight® [IMG: Tammy with bag and yoga mat] is not a valid ZIP code A valid ZIP code will have 5 numbers. Please try again. Your zip code is Change ZIP. Apply new ZIP code. Update ZIP Technical error We are experiencing an unexpected technical error. Please try again later. Please enter your zip code Update Zip [H2] Michael Norwood “I love helping people. The patient connection is my favorite part. Finding opportunities to impact communities while challenging myself to learn something new every day.” Get started Hello! I look forward to connecting with you. Please provide the following information and I’ll be in touch: [H2] Thank you! You have successfully signed up for Esperoct® updates. We’ll be in touch! I'm finished [H3] Contact a Novo Nordisk Rare Blood Community Liaison (RBCL) Life with a bleeding disorder can bring challenges, questions, and the occasional bump in the road. That’s why Novo Nordisk goes beyond treatment to provide information, education, and resources that might help. Our Rare Blood Community Liaisons (RBCLs) are experienced, active in the hemophilia community, and ready to provide you with one-on-one support, including: Information about Esperoct®, Novoeight®, and trial prescriptions Bleeding disorder and lifestyle education Updates on local events Tools to help you manage your bleeding disorder Contact a Novo Nordisk Rare Blood Community Liaison (RBCL) Life with a bleeding disorder can bring challenges, questions, and the occasional bump in the road. That’s why Novo Nordisk goes beyond treatment to provide information, education, and resources that might help. Our Rare Blood Community Liaisons (RBCLs) are experienced, active in the hemophilia community, and ready to provide you with one-on-one support, including: Information about Esperoct®, Novoeight®, and trial prescriptions Bleeding disorder and lifestyle education Updates on local events Tools to help you manage your bleeding disorder
9894 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
0Review mentions (all pages)
0External proof links (all pages)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 0 |
| /flex-factor.html | 0 | 0 |
| /community-voices.html | 0 | 0 |
| /women-in-hemophilia.html | 0 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema
{
"@context": "https://schema.org",
"@type": "MedicalWebPage",
"url": "https://www.esperoct.com/",
"headline": "Hemophilia A Treatment | Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]",
"description": "Esperoct® is indicated as an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Read important safety & prescribing info on this page.",
"name": "Esperoct®",
"audience": {
"@type": "MedicalAudience",
"audienceType": "Patient"
},
"specialty": {
"@type": "MedicalSpecialty",
"name": "Hematology"
},
"mainEntity": {
"@type": "Drug",
"name": "Esperoct®",
"nonProprietaryName": "antihemophilic factor (recombinant), glycopegylated-exei",
"activeIngredient": "antihemophilic factor (recombinant), glycopegylated-exei",
"alternateName": "Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]",
"dosageForm": "lyophilized powder",
"administrationRoute": "intravenous infusion",
"prescriptionStatus": "https://schema.org/PrescriptionOnly",
"prescribingInfo": "https://www.novo-pi.com/esperoct.pdf",
"warning": "Hypersensitivity reactions, including anaphylaxis, may occur. If a hypersensitivity reaction occurs, discontinue ESPEROCT® and administer appropriate treatment. (5.1) Development of neutralizing antibodies (inhibitors) has occurred. If bleeding is not controlled with the recommended dose of ESPEROCT®, or if the expected plasma Factor VIII activity levels are not attained, then perform an assay that measures Factor VIII inhibitor concentration. (5.2, 5.4) Temporary decrease in Factor VIII incremental recovery has been observed after ESPEROCT® infusion in previously untreated pediatric patients (PUPs). (5.3)",
"manufacturer": {
"@type": "Organization",
"name": "Novo Nordisk",
"logo": "https://www.esperoct.com/content/dam/novonordisk/universal/images/logos/logo-novo-nordisk.png"
}
},
"image": {
"@type": "ImageObject",
"name": "Esperoct® logo",
"contentUrl": "https://www.esperoct.com/content/dam/esperoct/site/patient/global/component/esperoct-logo.svg"
},
"about": [
{
"@type": "MedicalCondition",
"name": "Hemophilia A",
"alternateName": "factor VIII deficiency"
},
{
"@type": "MedicalTherapy",
"adverseOutcome": "rash or itching, and swelling, pain, rash or redness at the location of infusion",
"recognizingAuthority": {
"@type": "Organization",
"name": "U.S. Food and Drug Administration",
"alternateName": "FDA",
"url": "https://www.fda.gov/"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"item": {
"@id": "https://www.esperoct.com/",
"name": "Homepage"
}
}
]
},
"mainContentOfPage": [
{
"@type": "WebPageElement",
"headline": "Flexibility in hemophilia A",
"text": "Esperoct® offers the highest storage temperature (up to 104 °F) of all EHLs along with bleed protection for all ages.a aPrior to reconstitution, Esperoct® can be stored from 36 °F to 46 °F for up to 30 months, at room temperature up to 86 °F for up to 12 months, or up to 104 °F for up to 3 months. See Prescribing Information for complete product storage information.",
"potentialAction": {
"@type": "Action",
"name": "Explore Flex Factor",
"target": "https://www.esperoct.com/flex-factor.html"
}
},
{
"@type": "WebPageElement",
"headline": "Connect with us!"
},
{
"@type": "WebPageElement",
"headline": "Every experience matters",
"text": "We’re shining a spotlight on a few community voices and their stories about living and managing life with hemophilia A.",
"potentialAction": {
"@type": "Action",
"name": "See patient stories",
"target": "https://www.esperoct.com/community-voices.html"
}
},
{
"@type": "WebPageElement",
"headline": "Yes, women can have hemophilia too.",
"text": "You deserve a diagnosis and treatment options for your hemophilia. It’s time to challenge the misconception that women and girls can only be “carriers\" of hemophilia. Many women feel that their doctors dismiss or minimize their actual symptoms, but we’ve developed tools to help you make sure that you’re heard.",
"potentialAction": {
"@type": "Action",
"name": "Ready to start the conversation?",
"target": "https://www.esperoct.com/women-in-hemophilia.html"
}
},
{
"@type": "WebPageElement",
"headline": "Set a reminder for your calendar",
"text": "Stay on track with your Esperoct® infusion schedule and set up an infusion reminder that goes directly to your calendar."
}
]
}
/flex-factor.html
{
"@context": "https://schema.org",
"@type": "MedicalWebPage",
"url": "https://www.esperoct.com/flex-factor.html",
"headline": "Storage and Portability | Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]",
"description": "Learn about the storage temperature and flexible portability of Esperoct®. Use the heat map to explore regions of the United States and learn about their temperatures. Read important safety & prescribing info on this page.",
"name": "Esperoct®",
"audience": {
"@type": "MedicalAudience",
"audienceType": "Patient"
},
"specialty": {
"@type": "MedicalSpecialty",
"name": "Hematology"
},
"mainEntity": {
"@type": "Drug",
"name": "Esperoct®",
"nonProprietaryName": "antihemophilic factor (recombinant), glycopegylated-exei",
"activeIngredient": "antihemophilic factor (recombinant), glycopegylated-exei",
"alternateName": "Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]",
"dosageForm": "lyophilized powder",
"administrationRoute": "intravenous infusion",
"prescriptionStatus": "https://schema.org/PrescriptionOnly",
"prescribingInfo": "https://www.novo-pi.com/esperoct.pdf",
"warning": "Hypersensitivity reactions, including anaphylaxis, may occur. If a hypersensitivity reaction occurs, discontinue ESPEROCT® and administer appropriate treatment. (5.1) Development of neutralizing antibodies (inhibitors) has occurred. If bleeding is not controlled with the recommended dose of ESPEROCT®, or if the expected plasma Factor VIII activity levels are not attained, then perform an assay that measures Factor VIII inhibitor concentration. (5.2, 5.4) Temporary decrease in Factor VIII incremental recovery has been observed after ESPEROCT® infusion in previously untreated pediatric patients (PUPs). (5.3)",
"manufacturer": {
"@type": "Organization",
"name": "Novo Nordisk",
"logo": "https://www.esperoct.com/content/dam/novonordisk/universal/images/logos/logo-novo-nordisk.png"
}
},
"image": {
"@type": "ImageObject",
"name": "Esperoct® logo",
"contentUrl": "https://www.esperoct.com/content/dam/esperoct/site/patient/global/component/esperoct-logo.svg"
},
"about": [
{
"@type": "MedicalCondition",
"name": "Hemophilia A",
"alternateName": "factor VIII deficiency"
},
{
"@type": "MedicalTherapy",
"adverseOutcome": "rash or itching, and swelling, pain, rash or redness at the location of infusion",
"recognizingAuthority": {
"@type": "Organization",
"name": "U.S. Food and Drug Administration",
"alternateName": "FDA",
"url": "https://www.fda.gov/"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"item": {
"@id": "https://www.esperoct.com/",
"name": "Homepage"
}
},
{
"@type": "ListItem",
"position": 2,
"item": {
"@id": "https://www.esperoct.com/flex-factor.html",
"name": "Flex Factor"
}
}
]
},
"mainContentOfPage": [
{
"@type": "WebPageElement",
"headline": "Stay prepared with a flexible EHL treatment, even if things heat up",
"text": "Esperoct® offers the broadest temperature stability, for all ages.a Along with compact packaging for portability when you’re on the go."
},
{
"@type": "WebPageElement",
"headline": "The highest storage temperature of all extended half-life (EHL) products",
"text": "Esperoct® is the only EHL product that can be stored from 86 ºF to 104 ºF (for up to 3 months)."
},
{
"@type": "WebPageElement",
"headline": "Why does storage temperature matter?",
"text": "If a treatment becomes too hot or too cold, it could affect how it works. The high temperature stability of Esperoct® (from 36 °F to 104 °F) can help you stay prepared for life’s adventures or unexpected moments."
},
{
"@type": "WebPageElement",
"headline": "Feel prepared for a day of adventure or be ready for wherever life takes you",
"text": "Enjoy a day at the beach come rain or shine Take that vacation and bring Esperoct® with you Feel protected in a power outage"
},
{
"@type": "WebPageElement",
"headline": "Temperatures can fluctuate when you’re on the go.",
"text": "Explore the regions on this map to learn more about temperatures across the country."
},
{
"@type": "WebPageElement",
"headline": "Stay protected on the go",
"text": "Carry Esperoct® and your supplies with you in a portable, reusable kit that has been designed to fit into your life."
},
{
"@type": "WebPageElement",
"headline": "“I really like that Esperoct® is stable at room temperature and up to 104 ºF. I can just throw it in my backpack and go.”",
"text": "Hear more from Tammy and other voices in the hemophilia A community.",
"potentialAction": {
"name": "Hear their stories",
"target": "https://www.esperoct.com/community-voices.html"
}
},
{
"@type": "WebPageElement",
"headline": "Stay protected from bleeds",
"text": "With Esperoct® you can dose less often without sacrificing protection.",
"potentialAction": {
"name": "Find out more",
"target": "https://www.esperoct.com/bleed-control.html"
}
},
{
"@type": "WebPageElement",
"headline": "Ready to get started?",
"text": "We’ll guide you through the steps to take before your first infusion.",
"potentialAction": {
"name": "Get started",
"target": "https://www.esperoct.com/getting-started.html"
}
}
]
}
/community-voices.html
{
"@context": "https://schema.org",
"@type": "MedicalWebPage",
"url": "https://www.esperoct.com/community-voices.html",
"headline": "Community Voices | Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]",
"description": "Hear from patients about their experience with Esperoct®. Read important safety & prescribing info on this page.",
"name": "Esperoct®",
"audience": {
"@type": "MedicalAudience",
"audienceType": "Patient"
},
"specialty": {
"@type": "MedicalSpecialty",
"name": "Hematology"
},
"mainEntity": {
"@type": "Drug",
"name": "Esperoct®",
"nonProprietaryName": "antihemophilic factor (recombinant), glycopegylated-exei",
"activeIngredient": "antihemophilic factor (recombinant), glycopegylated-exei",
"alternateName": "Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]",
"dosageForm": "lyophilized powder",
"administrationRoute": "intravenous infusion",
"prescriptionStatus": "https://schema.org/PrescriptionOnly",
"prescribingInfo": "https://www.novo-pi.com/esperoct.pdf",
"warning": "Hypersensitivity reactions, including anaphylaxis, may occur. If a hypersensitivity reaction occurs, discontinue ESPEROCT® and administer appropriate treatment. (5.1) Development of neutralizing antibodies (inhibitors) has occurred. If bleeding is not controlled with the recommended dose of ESPEROCT®, or if the expected plasma Factor VIII activity levels are not attained, then perform an assay that measures Factor VIII inhibitor concentration. (5.2, 5.4) Temporary decrease in Factor VIII incremental recovery has been observed after ESPEROCT® infusion in previously untreated pediatric patients (PUPs). (5.3)",
"manufacturer": {
"@type": "Organization",
"name": "Novo Nordisk",
"logo": "https://www.esperoct.com/content/dam/novonordisk/universal/images/logos/logo-novo-nordisk.png"
}
},
"image": {
"@type": "ImageObject",
"name": "Esperoct® logo",
"contentUrl": "https://www.esperoct.com/content/dam/esperoct/site/patient/global/component/esperoct-logo.svg"
},
"about": [
{
"@type": "MedicalCondition",
"name": "Hemophilia A",
"alternateName": "factor VIII deficiency"
},
{
"@type": "MedicalTherapy",
"adverseOutcome": "rash or itching, and swelling, pain, rash or redness at the location of infusion",
"recognizingAuthority": {
"@type": "Organization",
"name": "U.S. Food and Drug Administration",
"alternateName": "FDA",
"url": "https://www.fda.gov/"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"item": {
"@id": "https://www.esperoct.com/",
"name": "Homepage"
}
},
{
"@type": "ListItem",
"position": 2,
"item": {
"@id": "https://www.esperoct.com/community-voices.html",
"name": "Community Voices"
}
}
]
},
"mainContentOfPage": [
{
"@type": "WebPageElement",
"headline": "“Hemophilia–has it impacted me? Yes. But does it stop me? No.”",
"text": "Vaughn lives with hemophilia A and uses Esperoct®"
},
{
"@type": "WebPageElement",
"headline": "Every experience matters",
"text": "Hear inspirational stories from people like you, who use Esperoct®."
},
{
"@type": "WebPageElement",
"headline": "Community matters",
"text": "“This community is so amazing. Everybody connects right away.” Craig lives with hemophilia A, works for Novo Nordisk, and uses Esperoct®"
},
{
"@type": "WebPageElement",
"headline": "Get support along the way"
},
{
"@type": "WebPageElement",
"headline": "Looking for more resources?",
"text": "We’ve gathered resources that you may find helpful.",
"potentialAction": {
"name": "View the resources",
"target": "https://www.esperoct.com/resources/support-for-you.html"
}
}
]
}
/women-in-hemophilia.html
{
"@context": "https://schema.org",
"@type": "MedicalWebPage",
"url": "https://www.esperoct.com/women-in-hemophilia.html",
"headline": "Women With Hemophilia A | Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]",
"description": "Esperoct® is an injectable treatment for all individuals with hemophilia A, including women and girls, to prevent or reduce bleeding episodes. Read important safety & prescribing info on this page.",
"name": "Esperoct®",
"audience": {
"@type": "MedicalAudience",
"audienceType": "Patient"
},
"specialty": {
"@type": "MedicalSpecialty",
"name": "Hematology"
},
"mainEntity": {
"@type": "Drug",
"name": "Esperoct®",
"nonProprietaryName": "antihemophilic factor (recombinant), glycopegylated-exei",
"activeIngredient": "antihemophilic factor (recombinant), glycopegylated-exei",
"alternateName": "Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]",
"dosageForm": "lyophilized powder",
"administrationRoute": "intravenous infusion",
"prescriptionStatus": "https://schema.org/PrescriptionOnly",
"prescribingInfo": "https://www.novo-pi.com/esperoct.pdf",
"warning": "Hypersensitivity reactions, including anaphylaxis, may occur. If a hypersensitivity reaction occurs, discontinue ESPEROCT® and administer appropriate treatment. (5.1) Development of neutralizing antibodies (inhibitors) has occurred. If bleeding is not controlled with the recommended dose of ESPEROCT®, or if the expected plasma Factor VIII activity levels are not attained, then perform an assay that measures Factor VIII inhibitor concentration. (5.2, 5.4) Temporary decrease in Factor VIII incremental recovery has been observed after ESPEROCT® infusion in previously untreated pediatric patients (PUPs). (5.3)",
"manufacturer": {
"@type": "Organization",
"name": "Novo Nordisk",
"logo": "https://www.esperoct.com/content/dam/novonordisk/universal/images/logos/logo-novo-nordisk.png"
}
},
"image": {
"@type": "ImageObject",
"name": "Esperoct® logo",
"contentUrl": "https://www.esperoct.com/content/dam/esperoct/site/patient/global/component/esperoct-logo.svg"
},
"about": [
{
"@type": "MedicalCondition",
"name": "Hemophilia A",
"alternateName": "factor VIII deficiency"
},
{
"@type": "MedicalTherapy",
"adverseOutcome": "rash or itching, and swelling, pain, rash or redness at the location of infusion",
"recognizingAuthority": {
"@type": "Organization",
"name": "U.S. Food and Drug Administration",
"alternateName": "FDA",
"url": "https://www.fda.gov/"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"item": {
"@id": "https://www.esperoct.com/",
"name": "Homepage"
}
},
{
"@type": "ListItem",
"position": 2,
"item": {
"@id": "https://www.esperoct.com/women-in-hemophilia.html",
"name": "Women in Hemophilia"
}
}
]
},
"mainContentOfPage": [
{
"@type": "WebPageElement",
"headline": "Are you a woman or girl who lives with hemophilia A or suspects you may have it?",
"text": [
"You’re not alone.",
"You deserve a diagnosis and treatment options for your hemophilia—but women with hemophilia A may not always be diagnosed. That’s why we’ve developed a Self-Advocacy Guide to help you share symptoms with your doctor and get the right treatment for you."
],
"potentialAction": {
"name": "Download the Self-Advocacy Guide",
"target": "https://www.esperoct.com/content/dam/esperoct/site/patient/resources/document/women-with-hemophilia-self-advocacy-tool.pdf"
}
},
{
"@type": "WebPageElement",
"headline": "Do you feel like your doctor is not listening to you?",
"text": [
"of the women and girls who had hemophilia or were carriers who visited a Hemophilia Treatment Center (HTC) were diagnosed with hemophilia.a",
"According to a healthcare provider survey: felt women with inherited bleeding disorders experience less access to care as compared to men & felt women experienced delays with a hemophilia diagnosis when their primary or only symptom was heavy period",
"According to the NBDF, as many as 50% of girls and women who are carriers for hemophilia A or B have factor 8 or 9 levels are below 50% and are at risk for bleeding symptoms or heavy bleeding related to menstruation of pregnancy. All people with inherited bleeding disorders should have access to care within a Hemophilia Treatment Center or other clinical program with expertise in bleeding disorders. If you are experiencing bleeding symptoms, it’s time for you and your doctor to talk about it."
],
"potentialAction": {
"name": "Download Your Guide",
"target": "https://www.esperoct.com/content/dam/esperoct/site/patient/resources/document/women-with-hemophilia-self-advocacy-tool.pdf"
}
},
{
"@type": "WebPageElement",
"headline": "Track Your Symptoms & Share With Your Doctor",
"text": [
"Your symptoms matter. Nearly 2 out of 3 hemophilia “carriers” had heavy menstrual bleeding in one study— periods lasting longer than 7 days, changing pads after less than 2 hours, and/or passing blood clots larger than 1 inch or the size of a quarter. This can be linked to:",
"Signs and symptoms of hemophilia in women and girls should not be dismissed. Remember, you know your body best. You can use the Self-Advocacy Guide to record any pain, swelling, and bruising you feel, which could be signs of a bleed. Bring these records with you to your doctor to help guide your conversation. Start tracking: Know your symptoms to better advocate for yourself"
],
"potentialAction": {
"name": "Get your Self-Advocacy Guide",
"target": "https://www.esperoct.com/content/dam/esperoct/site/patient/resources/document/women-with-hemophilia-self-advocacy-tool.pdf"
}
},
{
"@type": "WebPageElement",
"headline": "Tammy’s Been There Too",
"text": "Like many women, Tammy struggled to get the right treatment for her hemophilia. Now, she uses Esperoct® to treat her hemophilia A and is focusing on living her life on her terms. Meet Tammy: Sharing our stories makes a difference"
},
{
"@type": "WebPageElement",
"headline": "You deserve a diagnosis and treatment options for your hemophilia",
"text": [
"Flexxibility Factors on your termsc",
"Explore 2 options for women, girls, and people assigned female at birth with hemophilia A. "
]
},
{
"@type": "WebPageElement",
"headline": "Esperoct® is an extended half-life (EHL) treatment that can be used as prophylaxis or on demand.",
"potentialAction": {
"name": "Learn more",
"target": "https://www.esperoct.com/women-in-hemophilia/choosing-an-ehl.html"
}
},
{
"@type": "WebPageElement",
"headline": "Novoeight® is a standard half-life (SHL) treatment that can be used as prophylaxis or on demand. ",
"potentialAction": {
"name": "Learn more",
"target": "https://www.esperoct.com/women-in-hemophilia/choosing-an-shl.html"
}
},
{
"@type": "WebPageElement",
"headline": "You’re In Charge",
"text": "If you are experiencing bleeding symptoms, don't let your healthcare provider gloss over it. Provide your doctor with documentation of your symptoms. Make sure you follow up and ask questions—if something doesn’t make sense, say so. Prepare for your appointment so you can feel confident speaking up for yourself. Check out more tips in your Self-Advocacy Guide!"
},
{
"@type": "WebPageElement",
"headline": "It’s Time to Prioritize Your Health",
"text": "According to WFH guidance, women, girls, and people assigned female at birth with hemophilia A should be treated the same as men and boys—but when it comes to treatment, they may not have been. That’s why we’ve developed the Self Advocacy Guide to help you talk to your doctor about your hemophilia symptoms, receive the correct diagnosis, and get the right treatment for you. Learn more: These treatment options could fit your lifestyle",
"potentialAction": {
"name": "Explore Esperoct®",
"target": "https://www.esperoct.com/women-in-hemophilia/choosing-an-ehl.html"
}
},
{
"@type": "WebPageElement",
"potentialAction": {
"name": "Get to know Novoeight®",
"target": "https://www.esperoct.com/women-in-hemophilia/choosing-an-shl.html"
}
},
{
"@type": "WebPageElement",
"headline": "Contact a Novo Nordisk Rare Blood Community Liaison (RBCL)",
"text": "Life with a bleeding disorder can bring challenges, questions, and the occasional bump in the road. That’s why Novo Nordisk goes beyond treatment to provide information, education, and resources that might help. Our Rare Blood Community Liaisons (RBCLs) are experienced, active in the hemophilia community, and ready to provide you with one-on-one support, including: Information about Esperoct®, Novoeight®, and trial prescriptions Bleeding disorder and lifestyle education Updates on local events Tools to help you manage your bleeding disorder"
}
]
}
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Information Density
0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence
0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof
0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint
0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority
0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score
0 / 100
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Information Density
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Semantic Alignment
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Trust & Proof
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Commodity Fingerprint
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Identity & Authority
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS
Based on 784 businesses audited.
BS Detector
Medical Devices, Pharma & Biotech BS: Esperoct (Novo Nordisk) (esperoct.com)
https://esperoct.com
📍 Industry: Medical Devices, Pharma & Biotech
14
BS / 100
This is a benchmark for low-BS pharmaceutical marketing where the ‘Flexibility’ signal is a direct, measurable consequence of the drug’s PEGylated molecular stability. Substance outweighs signal on every page.
Info Density
Power-words vs. Substance ratio.
7
23% BS
Semantic Coherence
Homepage promise vs. Sub-page reality.
0
0% BS
Trust & Proof
Verifiable evidence vs. Trust Theatre.
2
10% BS
Commodity Fingerprint
Detection of industry clichés/templates.
4
27% BS
Identity & Authority
Expert verifiability & Schema depth.
1
7% BS
To achieve a near-zero score, add a direct link to the published 2012-2020 real-world study cited in the Women’s section. Implement Person schema for the Community Liaisons to verify their roles. Consolidate the repeated storage temperature footnotes into a single high-visibility technical comparison table to reduce concept redundancy across the footer.
The content perfectly aligns with the Medical and Pharma category. It includes specific drug indications, non-proprietary names (antihemophilic factor (recombinant), glycopegylated-exei), and required safety warnings (5.1-5.4) characteristic of regulated pharmaceutical communications.
“The score of 14 is driven primarily by the high Information Density (7) and the high uniqueness of the technical value proposition. The site avoided penalties in Semantic Coherence (0) due to perfect alignment between the flexibility promise and the technical proof of temperature stability. Minimal points were lost for generic value prop cliches and minor authority gaps regarding liaison profiles.”
Verified Analysis Date: May 30, 2026
© 1EuroSEO Independent Evaluator — Non-Sponsored Result
Analysis Disclosure & Source Attribution
This training module utilizes a snapshot of public data from Esperoct (Novo Nordisk), captured on May 30, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to Esperoct (Novo Nordisk): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://esperoct.com to view the most current version of its content and learn from the source what this company is about and what it offers.